Compare DFNS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | MRKR |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 23.0M |
| IPO Year | N/A | 2010 |
| Metric | DFNS | MRKR |
|---|---|---|
| Price | $0.60 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 1.2M | 111.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $621.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.62 | $0.81 |
| 52 Week High | $2.68 | $4.07 |
| Indicator | DFNS | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 19.61 | 45.42 |
| Support Level | N/A | $1.14 |
| Resistance Level | $2.44 | $1.43 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 17.99 | 53.54 |
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.